http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Cancer Genetics to Present at the Annual 33rd ROTH Conference
-
Cancer Genetics to Present at the Annual 33rd ROTH Conference
-
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference
-
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference
-
Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
-
Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
-
Cancer Genetics Reports Third Quarter 2020 Financial Results
-
Cancer Genetics Reports Third Quarter 2020 Financial Results
-
Cancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment Conference
-
Cancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment Conference
-
Cancer Genetics and StemoniX Announce Joint Proof-of-Concept Program
-
Cancer Genetics and StemoniX Announce Joint Proof-of-Concept Program
-
Cancer Genetics (CGIX) and StemoniX Sign Definitive Agreement to Merge
-
Cancer Genetics and StemoniX Sign Definitive Agreement to Merge
-
Cancer Genetics and StemoniX Sign Definitive Agreement to Merge
-
Cancer Genetics Reports Second Quarter 2020 Financial Results
-
Cancer Genetics Reports Second Quarter 2020 Financial Results
-
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics Reports First Quarter 2019 Financial Results and Provides Strategic Business Update
-
Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics Issues Letter to Shareholders
-
Pre-Open Stock Movers 01/10: (DCIX) (VERI) (BBBY) Higher; (M) (MDB) (KSS) Lower (more...)
-
Cancer Genetics Strengthens Management Team with Appointment of William Finger as Executive Vice President, Precision Medicine and Pharma Services
-
Cancer Genetics (CGIX) Terminates Proposed Merger with NovellusDx
-
Cancer Genetics Terminates Proposed Merger with NovellusDx
-
Cancer Genetics Reports Third Quarter 2018 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics (CGIX) Announces Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin Test in China
-
Cancer Genetics Enters Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin® Test in China
-
Cancer Genetics and Cellaria Partner on Precision Medicine Tools
-
Cancer Genetics (CGIX) Enters Supply Agreement with Agilent Technologies (A)
-
Cancer Genetics Enters Supply Agreement with Agilent Technologies
-
Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials
-
Cancer Genetics (CGIX) and NovellusDx Enter Definitive Agreement to Merge
-
Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge
-
Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018
-
Cancer Genetics Closes $2.625 million Convertible Note Financing
-
Cancer Genetics Strengthens Management Team with Appointment of Michael McCartney as Chief Commercial Officer
-
Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics to Report First Quarter 2018 Financial Results on May 15, 2018
-
Cancer Genetics (CGIX) Reports Sale of India Operations to REPROCELL Inc. for $1.9M
-
Cancer Genetics Announces Sale of India Operations to REPROCELL Incorporated
-
Cancer Genetics' (CGIX) Tissue of Origin Test Receives Special FDA 510(k) Clearance
-
Cancer Genetics’ Unique Tissue of Origin Test (TOO®) Receives Special FDA 510(k) Clearance
-
Cancer Genetics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Strategic Business Updates
-
Cancer Genetics to Host Fourth Quarter and Full Year 2017 Financial Results
-
PierianDx Announces Partnership with Cancer Genetics to Provide Comprehensive Precision Oncology Testing and Workflow Solution

